文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肺癌放射治疗的研究现状与趋势:一项文献计量分析

Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis.

作者信息

Liu Yanhao, Jiang Shu, Lin Yaru, Yu Haiming, Yu Lan, Zhang Xiaotao

机构信息

Department of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.

出版信息

Front Oncol. 2022 Nov 10;12:1066557. doi: 10.3389/fonc.2022.1066557. eCollection 2022.


DOI:10.3389/fonc.2022.1066557
PMID:36439443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9685815/
Abstract

BACKGROUND: radiotherapy is one of the major treatments for lung cancer and has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer radiotherapy. METHOD: On August 31, 2022, the authors identified 9868 articles on lung cancer radiotherapy by the Web of Science (Science Citation Indexing Expanded database) and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top-papers) as well as top-journals on lung cancer radiotherapy. After that, the authors analyzed the recent research hotspots based on the latest publications in top-journals. RESULTS: These 9868 papers were cited a total of 268,068 times. "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer" published in 2017 by Antonia et al.was the most cited article (2110 citations). Among the journals, was most influential. Moreover, and was both influential and productive. Corresponding authors represented the USA (2610 articles) and China mainland (2060 articles) took part in most publications and articles with corresponding authors from Netherlands were most cited (46.12 citations per paper). Chemoradiotherapy was the hottest research area, and stereotactic body radiotherapy has become a research hotspot since 2006. Radiotherapy plus immunotherapy has been highly focused since 2019. CONCLUSIONS: This bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on 9868 relevant articles, and further suggests future research directions. The researchers can benefit in selecting journals and in finding potential collaborators. This study can help researchers gain a comprehensive picture of the research landscape, historical development, and recent hotspots in lung cancer radiotherapy and can provide inspiration for future research.

摘要

背景:放射治疗是肺癌的主要治疗方法之一,多年来一直是热门研究领域。本文献计量分析旨在呈现肺癌放射治疗的研究趋势。 方法:2022年8月31日,作者通过科学网(科学引文索引扩展数据库)检索到9868篇关于肺癌放射治疗的文章,并提取了它们的一般信息和总被引次数。进行文献计量分析以展示研究格局、呈现研究趋势,并确定肺癌放射治疗领域被引次数最多的论文(高被引论文)以及顶级期刊。之后,作者根据顶级期刊的最新出版物分析了近期研究热点。 结果:这9868篇论文共被引用268,068次。安东尼娅等人于2017年发表的《III期非小细胞肺癌同步放化疗后使用度伐利尤单抗》是被引次数最多的文章(2110次引用)。在期刊方面,《》最具影响力。此外,《》和《》既具影响力又高产。通讯作者代表美国(2610篇文章),中国大陆(2060篇文章)参与的出版物最多,来自荷兰的通讯作者的文章被引次数最多(每篇论文46.12次引用)。同步放化疗是最热门的研究领域,自2006年以来立体定向体部放射治疗已成为研究热点。自2019年以来,放射治疗联合免疫治疗一直备受关注。 结论:本文献计量分析基于9868篇相关文章全面定量地呈现了研究趋势和热点,并进一步提出了未来的研究方向。研究人员在选择期刊和寻找潜在合作者方面可从中受益。本研究有助于研究人员全面了解肺癌放射治疗的研究格局、历史发展和近期热点,并可为未来研究提供灵感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/6a14442a9476/fonc-12-1066557-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/8c4295d8729d/fonc-12-1066557-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/32c856c8f36e/fonc-12-1066557-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/b01b8da309c2/fonc-12-1066557-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/879f4c653cbe/fonc-12-1066557-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/9bf571778518/fonc-12-1066557-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/b530529c6a9f/fonc-12-1066557-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/6a14442a9476/fonc-12-1066557-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/8c4295d8729d/fonc-12-1066557-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/32c856c8f36e/fonc-12-1066557-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/b01b8da309c2/fonc-12-1066557-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/879f4c653cbe/fonc-12-1066557-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/9bf571778518/fonc-12-1066557-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/b530529c6a9f/fonc-12-1066557-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/9685815/6a14442a9476/fonc-12-1066557-g007.jpg

相似文献

[1]
Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis.

Front Oncol. 2022-11-10

[2]
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis.

Front Immunol. 2022

[3]
Research landscape and trends of melanoma immunotherapy: A bibliometric analysis.

Front Oncol. 2023-1-9

[4]
Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy.

Front Oncol. 2021-12-3

[5]
Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.

Front Immunol. 2022

[6]
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.

Heliyon. 2024-2-27

[7]
The 100 Most Cited Papers in Radiotherapy or Chemoradiotherapy for Cervical Cancer: 1990-2020.

Front Oncol. 2021-9-1

[8]
The top 100 highly cited articles on anterior cruciate ligament from 2000 to 2019: A bibliometric and visualized analysis.

Orthop Traumatol Surg Res. 2021-12

[9]
Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field.

Front Oncol. 2022-8-17

[10]
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).

Front Immunol. 2022

引用本文的文献

[1]
Improved commissioning of lung stereotactic body radiotherapy using a customized respiratory motion Phantom: a single- institutional study.

Phys Eng Sci Med. 2025-6

[2]
Global research and current trends on nanotherapy in lung cancer research: a bibliometric analysis of 20 years.

Discov Oncol. 2024-10-9

[3]
Mapping the global research landscape on depression for patients with chronic kidney disease: a bibliometric and visualized analysis from 2006 to 2022.

Front Pharmacol. 2024-7-17

[4]
The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).

Oncol Rep. 2024-7

[5]
Non-small cell lung cancer and metabolism research from 2013 to 2023: a visual analysis and bibliometric study.

Front Oncol. 2024-5-28

[6]
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.

Heliyon. 2024-2-27

[7]
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis.

Front Immunol. 2022

本文引用的文献

[1]
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.

BMC Cancer. 2022-9-24

[2]
Clinical Outcomes Following Proton and Photon Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer.

Cancers (Basel). 2022-8-27

[3]
Effect of preoperative radiotherapy on overall survival in N2 non-small-cell lung cancer: a propensity score-matched analysis of Surveillance, Epidemiology, and End Results database.

Interact Cardiovasc Thorac Surg. 2022-6-15

[4]
Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer.

Radiother Oncol. 2022-8

[5]
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.

Clin Lung Cancer. 2022-7

[6]
Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.

Front Immunol. 2022

[7]
Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial.

Int J Radiat Oncol Biol Phys. 2022-7-15

[8]
tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC).

Clin Transl Radiat Oncol. 2022-1-5

[9]
Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer.

Int J Radiat Oncol Biol Phys. 2022-6-1

[10]
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy.

Int J Radiat Oncol Biol Phys. 2022-6-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索